Respiratory distress syndrome in the newborn is associated with a deficiency of pulmonary surfactant, the main component of which is dipalmitoylphosphatidylcholine (1). A number of pharmacological agents have been found to influence the synthesis of pulmonary surfactant. The effect of glucocorticoids has been studied most extensively, and accelerated lung maturation has been demonstrated in experimental (2, 3) as well as clinical studies (4, 5) . Xanthines are widely used in lung diseases such as asthma and apnea in premature infants, but the mechanism of action of these drugs is still relatively unknown. Increased release of pulmonary surfactant into the alveolar space might be one effect of xanthines. Several animal studies indicate increased synthesis and/or secretion of fetal surfactant after administration of aminophylline (theophylline ethylenediamine) to the mother or directly to the fetus (3, 6, 7), but other studies have not confirmed this effect (8). Enprofylline (3-propylxanthine), a new xanthine derivative, exhibits potent antiasthmatic characteristics (9). However, the effects of this substance and those of theophylline differ in several respects; most importantly, theophylline is a potent adenosine antagonist, while enprofylline is not (10). Our investigation is an assessment of fetal surfactant release following enprofylline infusion to the doe.
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MATERIALS AND METHODS
Eight pregnant New Zealand rabbits were used. Time of mating was known within 1 h. At a gestational age of 27.9 days (term 3 1 days), four does were injected intravenously with enprofylline, 5 mg/kg, during a 5-min period, and, in an identical manner, four controls received the same volume of Ringer's solution. Following this loading dose, the rabbits were continuously infused over the next 2 h with enprofylline, 20 mg/kg, and the controls with the same volume of Ringer's solution. On completion of the infusion, the maternal rabbits were killed with a lethal intravenous dose of thiopental sodium and the abdomen was opened. To prevent the fetuses from making inspiratory efforts, they were injected intracranially with 0.5 ml thiopental sodium while still in utero. The fetuses then were delivered through uterine incisions. The trachea of each fetus was exposed, and a polyethylene tube (PE 50) was inserted just below the larynx. From each fetus, about 25 p1 of lung fluid was collected for evaluation of surface activity with the pulsating bubble surfactometer (1 1). This instrument is particularly appropriate for assessing the effect that surface properties of fetal pulmonary fluid will have on the initial aeration with the first breath and on subsequent breathing. The surfactometer's sample chamber, filled with the airway fluid, communicates with ambient air through a vertical capillary. As fluid is withdrawn from the chamber, air is forced to move down the capillary, the cylindrical "airway," and a bubble, with a radius of 0.55 mm, is developed. While the first breath is thus simulated, the negative pressure in the sample liquid surrounding the bubble is recorded. Subsequent "breathing" is by the action of a pulsator which causes the bubble radius, R, to oscillate from maximal to minimal size, from 0.55 to 0.4 mm. The pulsator speed is usually set at 20 cycles/min. Knowing the values of the pressure difference across the bubble's surface, AP, and of R, surface tension, y, can be calculated with the law of Laplace, AP = 2ylR. In this study, the adsorption rate, the speed with which a monolayer is formed at the bubble surface, was of particular interest. Pressure was therefore recorded while the bubble was first created and then maintained at maximal size for 10 s. The pulsator then was started. From the pressure tracing, y, was obtained 2 and 10 s after bubble creation while the radius was maintained at maximal size, and also in the third cycle of pulsation when the radius was at maximal and at minimal size. The value of AP decreases continuously during the 10 s the bubble is maintained at maximal size, and the rate of change reflects interface adsorption of surfactant molecules. Pulmonary fluid from a fetus at term, 3 1 days, shows very fast adsorption, and after 10 s, AP indicates that surface tension is approximately 27 mN m-', and this low value is already reached after 2 s. Lung compliance and stability were then assessed, as previously described (12), by photographic recording of the pressure-volume loops of all fetuses in a litter. Two consecutive loops were obtained by recording volume as pressure was changed from 0 to 10, 20, 30, 35, 30, 20, 10 , and back to 0 cm H20, each level being maintained for 15 s.
Following pressure-volume loop recording, the lungs were degassed by repeatedly exposing the whole fetuses to vacuum. The lungs were then lavaged with saline in a volume which in ml was one-tenth the body weight in g. This volume was divided into three equal portions for the same number of washings, each consisting of injecting and withdrawing the saline once only. The amount of liquid retrieved was 90-100% of the saline instilled.
The lipids were extracted according to the method of Folch et al. (1 3) , and the total phospholipid phosphorus was quantitated, as described by Rouser et al. (14) . Following lavage, the lungs were removed and dried for 24 h in an oven at 100" C. The volume of air in ml entering the lungs and the phospholipid content in pg of phospholipid phosphorus were expressed per g dry lung. To make certain that the enprofylline had indeed passed the placenta, concentration of the drug was determined in the myocardium of some of the fetuses and in maternal serum.
Student's t test was used for significance evaluation of the difference between mean values found in this study. p values >0.05 were considered not significant.
RESULTS
There were 3 1 fetuses from the four does receiving enprofylline and 32 from the four controls. The fetuses exposed to the drug weighed slightly more, 36. 16.9 + 0.5 pg/g tissue (mean f SE), and in maternal serum was 34.1 + 2.2 pg/ml (n = 4).
Infusion of enprofylline to the pregnant rabbit resulted in several significant changes, all indicating an increased release of pulmonary surfactant into the fetal airways. Surface tension decreased in fetal pulmonary fluid, total phospholipid phosphorus increased in the lavage (Table I) , and lung expansion was greater throughout the first (Fig. 1) as well as the second loop (Fig. 2) . When the volume of air retained at deflation pressure 10 cm H 2 0 was expressed as a percentage of the volume at maximal expansion, it was 64 f 3 (mean + SE) for the enprofylline-exposed fetuses and 49 f 3 for the controls in the first loop, and in the second loop the corresponding figures were 71 f 3 and 52 f 5. These figures indicate that the enprofyllineexposed fetuses had lungs with significantly greater stability ( p < 0.0005).
DISCUSSION
On the average, the fetuses receiving enprofylline weighed more than did the controls. Since the time of mating was carefully controlled, it is unlikely that this was due to a difference in gestational age, which could be no more than 1 h. Theophylline is a potent diuretic, perhaps because it inhibits intrarenal actions of endogenous adenosine. Enprofylline, exerting no such inhibition, is definitely not a diuretic and in high dose, 20 mg/kg, reduces urinary excretion of sodium in the rat (15). We believe that the higher weight ofthe fetuses exposed to enprofylline could be due to edema developing; there was no difference in the dry lung weight.
In our statistical analysis, the number of fetuses was our n value. Abbey and Howard (16) are of the opinion that this is inappropriate because the offspring of one female may differ from that of another and because the mother's reaction to a treatment may vary and could influence a whole litter. Instead, they suggest that the SD should be calculated from the means of the litters. Obviously, this will drastically reduce the degrees of freedom. It is undoubtedly true that maternal factors, such as gestational age, will affect an entire litter and hence should be 
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EKELUND AND ENHORNING kept equal for each doe. There are indisputable differences between individual fetuses within a litter, for instance, in body size. We therefore considered it appropriate to regard each fetus as an individual, receiving the drug infused to the mother in a dose equal to that affecting its littermates. We did, however, also calculate the p value in the conservative manner suggested by Abbey and Howard (16) , and found that the differences in phospholipid phosphorus content and in air retention at deflation pressure 10 cm H 2 0 of the first loop were still significant (p < 0.01 and < 0.05, respectively).
In the past, pulmonary surfactant has often been evaluated on the basis of one parameter only, its ability after several minutes to lower surface tension to close to zero on surface area compression. This reflects an important stabilizing effect, but surfactant clearly has other equally important qualities, such as quick adsorption and respreading (l7), which are difficult to appreciate with the modified Wilhelmy balance, as generally used. The initial aeration requires that surface tension be lowered at the air-liquid interfaces as these move down the cylindrical airways toward the alveoli. This requires the extremely fast adsorption that characterizes pulmonary fluid from a fetus at term. As soon as 2 s after bubble expansion in each fluid, a very low surface tension will be observed with the bubble surfactometer. Fast adsorption of surfactant into an expanding interface between pulmonary fluid and air will also result in increased compliance of the lung, so that with moderate time of raised pressure in the airways (we used 15 s for each pressure level) the lungs will become well aerated and total lung capacity is increased. Our results implied that adsorption was improved in the airway fluid of neonates exposed to enprofylline in utero; surface tension was already lower after 2 s and more air moved into the lung when tracheal pressure was raised. The greater volume of air retained in the lung during deflation, a sign of improved stability, was another indication that surfactant had been released into the airways of pups exposed to enprofylline. Finally, our finding of higher levels of total phospholipids in lavage fluid also offered strong evidence of surfactant release following enprofylline treatment.
Previous reports on the xanthine effects on synthesis and release of pulmonary surfactant have been conflicting. Following treatment with theophylline, increased synthesis of fetal pulmonary surfactant has been observed, in vitro as well as in vivo. Thus, Gross and coworkers (18, 19) found that the drug caused an increased incorporation of choline into phosphatidylcholine in fetal rat lung studied in organ culture. Following theophylline injections given to pregnant rabbits for 7-10 days, Karotkin et al. (20) noted increased amounts of phospholipids in fetal lung tissue and lavage fluid, and they found compliance to be higher. Their results are similar to those reported by Barrett et a[. (21) .
A recent article (22) reports on the effect of treating pregnant rabbits for 2 days with aminophylline, beginning at 25.5 days' gestation. This produced a significant total phospholipid increase in fetal lung tissue, but there was no such increase in lung lavage.
In short-term experiments, Corbet et al. (7) studied the release of fetal pulmonary surfactant. They injected fetal rabbits in utero with theophylline at a gestational age of 27.5 days. When sacrificed 2.5 h later, the lungs of theophylline-treated fetuses retained more air at deflation pressure 10 cm H20, and total phospholipids, recovered from lung lavage fluid were higher, indicating increased release of pulmonary surfactant. However, using similar methods and the same dose of theophylline, we were unable to confirm these results (8) and, in accordance with our observations in the rabbit, Gross et al. (personal communication) found that there was no increased release of fetal pulmonary surfactant after infusion of pregnant rats with different dosages of theophylline.
Our own results may seem conflicting. With theophylline, we were unable to find an increased surfactant release (8), whereas we have now found that, following exposure to enprofylline, surfactant is released into the fetal airway. This requires an analysis and a comparison of the mode of action of the two xanthines. It has been suggested that cAMP may be a mediator of synthesis and/or secretion of fetal pulmonary surfactant (21) . In high concentrations, xanthines increase cAMP by inhibiting phosphodiesterase, the enzyme inactivating cAMP (23) , and thus might stimulate the appearance of pulmonary surfactant into fetal airways. Xanthines are widely used in asthma therapy and their mechanisms of action on this disease have been studied extensively. A recent review by Persson (24) presents reasons why it is doubtful that a xanthine is of benefit to the asthmatic by virtue of being a phosphodiesterase inhibitor. At therapeutic plasma concentrations, the bronchorelaxant effect of theophylline is unlikely to be mediated by cAMP (25) . Enprofylline exhibits potent antiasthmatic characteristics, while lacking several of theophylline's side effects (9, 24) . This might be due to an important difference in the action of the two drugs. While theophylline is a potent adenosine antagonist (26, 27) , enprofylline is almost totally unable to compete for receptor sites (24) . Since adenosine regulates adenylate cyclase and increases intracellular cAMP in several cell systems (24, 25) , it probably promotes surfactant release, and it is conceivable that enprofylline has the ability to exert surfactant release because it lacks the adenosine antagonistic effects of other xanthines. This is an area obviously requiring further investigation. We are presently making direct comparisons between theophylline and enprofylline and we are evaluating the hypothesis that adenosine per se promotes surfactant release.
